Healthcare company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Thursday that it will discontinue its talc-based baby powder around the world from next year.
The product has already been withdrawn from the US market.
J&J reiterated its view that decades of independent research shows the product is safe to use, does not contain asbestos, and does not cause cancer.
The company is facing legal action from thousands of women who allege its talcum powder caused them to develop ovarian cancer.
J&J said it had made the commercial decision to transition to cornstarch-based baby powder.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients